arrow
S

Sam Schulman

mcmaster university
H指数:88
被引数:5.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical and Laboratory-Based Prognostic Factors for Pediatric Post-Thrombotic Syndrome: Findings from the Kids-DOTT Trial

儿童血栓后综合征的临床和实验室预后因素:Kids-DOTT试验的结果

2026-10-260
OAAI
The diagnostic performance of the YEARS and Pulmonary Embolism Graduated D-dimer algorithms in patients with prior venous thrombosis suspected of pulmonary embolism

YEARS算法和肺栓塞分级D-二聚体算法在既往静脉血栓形成并怀疑肺栓塞患者中的诊断性能

2026-05-010
OAAI
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism

阿哌沙班与利伐沙班在急性静脉血栓栓塞症中的出血风险比较

2026-03-128
PRE
Rates and risk factors for major adverse cardiovascular and cerebrovascular events after stroke due to intracerebral hemorrhage: Systematic review and study-level meta-analysis

颅内出血导致卒中后主要不良心血管和脑血管事件的发生率及危险因素:系统评价和基于研究水平的荟萃分析

2026-01-280
OA
Sustainable anticoagulation for climate resilient care

气候适应型护理的可持续抗凝治疗

2025-09-160
PRE
Performance of clinical decision rules in patients presenting with suspected recurrent venous thromboembolism: a multicenter prospective cohort study

临床决策规则在疑似复发性静脉血栓栓塞症患者中的表现:一项多中心前瞻性队列研究

2025-06-250
PRE
Investigating interassay variability between direct oral anticoagulant calibrated anti–factor Xa assays: a substudy of the perioperative anticoagulation use for surgery evaluation (PAUSE) trial

调查直接口服抗凝剂校准的抗凝血酶Xa因子试验间的批间变异性:一项围手术期手术抗凝使用评估(PAUSE)试验的子研究

2025-05-010
OA
Duration of primary/secondary treatment to prevent recurrent venous thromboembolism: a systematic review and meta-analysis

预防复发性静脉血栓栓塞症的一级/二级治疗持续时间:一项系统评价和Meta分析

2025-04-080
OA
Perioperative management of direct oral anticoagulants in patients having a high-bleed-risk surgery or neuraxial procedure: the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE)-2 pilot randomized trial

直接口服抗凝剂在高出血风险手术或神经轴手术患者中的围手术期管理:围手术期抗凝剂用于手术评估(PAUSE-2)试点随机试验

2025-03-120
PRE
Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 years
2025-02-010
PRE